Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.48 |
| ▸ | FAP | Q12884 | 2/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15323564 | 0.94 | DPP4 (0.48) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL20362682 | 0.82 | DPP4 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL28993929 | 0.80 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1504141 | 0.79 | SIRT6 (0.34) | DPP4FAPPIK3CD | |
| SCHEMBL13360296 | 0.76 | DPP4 (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30317617 | 0.75 | L3MBTL1 (0.41) | — | |
| SCHEMBL24943291 | 0.74 | GNAI3 (0.40) | — | |
| SCHEMBL15177041 | 0.74 | GNAI3 (0.40) | — | |
| SCHEMBL22375785 | 0.72 | DPP4 (0.45) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10272668 | 0.72 | CHRNB2 (0.39) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1036 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743576-A1 | RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF | Korro Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026101913-A1 | SIRNAS TARGETING COMPLEMENT FACTOR H-RELATED (CFHR) GENE TRANSCRIPTS AND METHODS OF USE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4740951-A2 | IGH REARRANGEMENTS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4729120-A2 | METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIA | Genzyme Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103715-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12594253-B2 | HIV inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNGDER WISSENSCHAFTEN E.V. (DE) | 2026-04-07 | — | — | US | disclosed |
| EP-4267767-B1 | IGH REARRANGEMENTS AND USES THEREOF | FOUND MEDICINE INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12590305-B2 | Complement component C5 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-2723758-A2 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSTIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20130317081-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2013-11-28 | — | — | US | disclosed |
| WO-2013163430-A2 | SERPINC1 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130289094-A1 | Compositions and Methods for Inhibition of PCSK9 Genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
| EP-2633046-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF PCSK9 GENES | Alnylam Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130184324-A1 | Dual Targeting siRNA Agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012177784-A2 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSTIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012058693-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF PCSK9 GENES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2011038031-A1 | DUAL TARGETING SIRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590305-B2 | Complement component C5 iRNA compositions and methods of use thereof | UPF1, C5, NSUN2 | DPP4 3927/4885DPP8 2848/4885DPP9 1433/4885 |
| US-12594253-B2 | HIV inhibitors | TRMT1, NSUN2, NSUN3 | DPP4 2709/4885DPP8 2074/4885DPP9 905/4885 |
| US-20260103715-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | PDCD1LG2, CD274, PDCD1 | DPP4 2059/4885DPP8 1343/4885DPP9 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.